In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile | Zendy

E L Fasola | Zendy; Julia Moody | Zendy; Dale N. Gerding | Zendy; Lance R. Peterson | Zendy

Open Access

In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile

Author(s) -

E L Fasola,

Julia Moody,

Dale N. Gerding,

Lance R. Peterson

Publication year - 1990

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.34.10.2007

Subject(s) - vancomycin , microbiology and biotechnology , clostridium difficile , staphylococcus aureus , glycopeptide , methicillin resistant staphylococcus aureus , antibiotics , in vitro , micrococcaceae , clostridium , biology , antibacterial agent , bacteria , biochemistry , genetics

The in vitro activity of LY 264826, a new glycopeptide antibiotic, was compared with that of vancomycin against 100 strains each of methicillin-resistant Staphylococcus aureus and Clostridium difficile. LY 264826 was more active, by weight, than vancomycin against the isolates tested. The human serum protein binding of LY 264826 was 15.3% (range, 9.8 to 21.8%).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research